|MDACC Study No:||2010-0788 (clinicaltrials.gov NCT No: NCT01289457)|
|Title:||Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|
|Principal Investigator:||Elias Jabbour|
|Treatment Agent:||Clofarabine; Cytarabine; Fludarabine; Idarubicin|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
clofarabine, idarubicin, and cytarabine, or the combination of fludarabine,
idarubicin, and cytarabine can help control AML and MDS. The safety of these
study drug combinations will also be studied.